Ambit in the Media
On Target: Ambit Biosciences participates in expert panel discussion exploring target validation – Dec 2009
Patrick Zarrinkar participates in an expert panel discussion moderated by Merck's Wendy Cornell, Director, Chemistry Modeling & Informatics, on the topic of drug discovery targets.
Access the full article [402KB]
Listen to the interview - MP3 (19MB)
Kinase Inhibitors: Combating Disease – Dec 2009
Wendell Wierenga speaks with Future Pharmaceuticals on kinase inhibitors, Ambit's rapidly burgeoning pipeline, and how KINOMEscan enables discovery efforts by rapid and efficient delivery of advanced starting points.
Access the full article [317KB]
Listen to the interview - MP3 (10MB)
Xconomy discusses Ambit history, upcoming clinical program with CEO Scott Salka
Ambit CEO Scott Salka takes time out with Xconomy to discuss Ambit's history and reincarnation as a drug discovery company as well as their upcoming commencement of a comprehensive clinical program to support the registration of their lead asset AC220. Says Scott Salka, "For people who don't keep a close eye on us, they can't believe how quickly things have moved..."
Characterization and Comparison of Ambit's AC220 published in Blood - Aug 2009
A paper published in Blood reports the characterization of AC220, a second generation FLT3 receptor tyrosine kinase inhibitor for treatment of acute myeloid leukemia, and comparison to a panel of first generation FLT3 inhibitors. AC220 is described as exhibiting a unique combination of nanomolar potency, exceptional selectivity and oral pharmacokinetic properties desirable for a clinical FLT3 inhibitor. Ambit's KINOMEscan kinase screening platform was instrumental in the discovery and optimization of AC220.
BioWorld Today discusses Ambit's Series D Financing – November 2007
In a frontpage article focused on Ambit's $43.9 million Series D Financing, BioWorld Today discusses the company's new and existing investors as well as its kinase inhibitor programs and new additions to its board of directors.
Access the full article [64KB]
bizSanDiego features the history of Ambit Biosciences and gets up close and personal with CEO, Scott Salka – January 2007
In its January cover story, bizSanDiego examines the history of Ambit from the company's humble beginnings to their current status of one of San Diego's fastest growing biotech companies. The article also discusses CEO Scott Salka's industry experience and reveals his recipe for success. Copyright 2006 bizSanDiego, photos courtesy of Matthew McFarland.
Access the full article [928KB]
Drug Discovery News discusses Ambit's collaboration with Cephalon – December 2006
In an article focused on Ambit's screening, discovery and development agreement with Cephalon, Drug Discovery News reported why Ambit's partner felt that Ambit is the kinase screening collaborator of choice: "After evaluating several technologies, we felt that Ambit had several important attributes that included: world-class technology, a scientific and management team that understood and were committed to drug discovery and an impressive track record of accomplishment."
Study validating KINOMEscan is featured in Cancer Research – January 2006
A study published in Cancer Research discusses the crystal structure of the imatinib (Gleevec(r))-resistant BCR-Abl kinase in complex with VX-680, a small molecule initially developed by Vertex Pharmaceuticals as an Aurora kinase inhibitor. Using KINOMEscan, researchers initially identified VX-680's action on imatinib-resistant BCR-Abl (PNAS, 2005). The study here further validates KINOMEscan's strength in identifying small molecules that activate or inhibit therapeutically relevant kinases, both wild-type and mutant. Copyright 2006 Cancer Res.
Access the full article [432KB]
Dow Jones VentureWire Reviews Ambit's Growth – January 2006
In an article focused on Ambit's expanded collaboration with Bristol-Myers Squibb, Dow Jones VentureWire also discusses Ambit's recent financing activity and key hires.
Study Using Ambit's KINOMEscan Featured in PNAS - July 2005
A study published in the Proceedings of the National Academy of Sciences utilized Ambit's KINOMEscan technology to reveal several existing clinical drug candidates that bind to and inhibit various mutations responsible for the development of resistance to the leading targeted cancer drugs Gleevec®, IRESSA® and TARCEVA™. Copyright (2005) Proc. Natl. Acad. Sci. USA
Ambit Profiled in San Diego Union-Tribune - April 2005
In its profile of Ambit, the San Diego Union-Tribune reported why one of Ambit's VCs became interested in the company: "The scientists said that within a week... the technology allowed them to find the target of FK506, an immunosuppressive drug. ...Earlier, Vertex had spent millions of dollars and over a year trying to find the drug's target."
Ambit's KINOMEscan Featured in Nature Biotechnology - March 2005
A paper published in Nature Biotechnology describes Ambit's KINOMEscan technology and outlines data generated by screening 20 important kinase inhibitors against Ambit's extensive kinase panel. The study examines several kinase inhibitors, including Gleevec®, Iressa®, and Tarceva™, and their interactions with a large number of human kinases.
View the entire study [436KB] | View supplement to study [94KB]
BioCentury Profiles Ambit - January 2005
BioCentury's The Bernstein Report recently described Ambit's efficient and extensive KINOMEscan technology by saying, "Ambit can move quickly because its binding assay is more scalable than traditional enzyme activity assays."
Access the full article [662KB]
BioWorld Details Ambit's Successful Collaborations - January 2005
Ambit was profiled in a front-page BioWorld article detailing Ambit's successful collaborations with large industry-leading organizations. "Ambit's super-multi-tasking approach to kinase screening bagged the company deals with three of pharma's top players - Bristol-Myers Squibb Co., GlaxoSmithKline plc and Pfizer Inc.," the article begins.
Access the full article [123KB]
Adobe Reader required to view these articles. Download Adobe Reader here.